Identification of highly-protective combinations of <i>Plasmodium vivax</i> recombinant proteins for vaccine development.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28949293.
- Also identified by DOI 10.7554/eLife.28673 and PMC identifier 5655538.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 <i>P. vivax</i> antigens, investigating their relationship with prospective risk of malaria in a cohort of 1-3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44-0.74, p<0.001-0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent <i>P. vivax</i> vaccine.
Medical subject headings
- Antibodies, Protozoan
- Antigens, Protozoan
- Malaria, Vivax
- Plasmodium vivax
- Protozoan Proteins
- Recombinant Proteins